CWS
VTGN icon

Confluence Wealth Services’s VistaGen Therapeutics VTGN Stock Holding History

Confluence Wealth Services’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.37K Buy
+32,610
New +$19.7K ﹤0.01% 476
2022
Q1 		– Sell
-57
Closed -$3K – 1153
2021
Q4 		$3K Buy
+57
New +$3.71K ﹤0.01% 1125

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Confluence Wealth Services's VTGN Position: Q2 2026 in Review

Confluence Wealth Services opened a new position in VistaGen Therapeutics (VTGN) in Q2 2026: 32,610 shares worth $7.37K. The stake represents ﹤0.01% of the portfolio and ranks #476 among its holdings. This is a return to the name: Confluence Wealth Services previously reported a position in VTGN as recently as Q4 2021.

Confluence Wealth Services first reported a position in VTGN in Q4 2021 and has held it in 2 quarters since. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Confluence Wealth Services held 32,610 shares of VistaGen Therapeutics worth $7.37K as of Q2 2026.
  • VistaGen Therapeutics was a new Confluence Wealth Services position in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Confluence Wealth Services's portfolio in Q2 2026, its #476 holding.
  • Confluence Wealth Services first reported a position in VistaGen Therapeutics in Q4 2021 and has held it in 2 quarters since.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Confluence Wealth Services's 13F filing for Q2 2026, filed 22 Jul 2026.